Talk:Huperzine A

IUPAC Name lacks stereochemistry

IUPAC Name lacks stereochemistry. Suggested name awaiting validation (1R,9S,13E)-1-amino-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.0^(2,7)]trideca-2(7),3,10-trien-5-one--ChemSpiderMan (talk) 17:24, 14 January 2008 (UTC)[reply]

Now fixed. Walkerma (talk) 05:58, 20 January 2008 (UTC)[reply]

The assigned stereochemistry is wrong it is a (1R, 9R, 13E)-.... check any source (chemspider, scifinder and so on) — Preceding unsigned comment added by 130.208.176.1 (talk) 14:15, 26 November 2015 (UTC)[reply]

possible 10 IQ point raise, confusing reference

this pubmed reference says of schizophrenics given huperzine A "RESULTS:

Twelve RCTs (n = 1117) lasting 11.7 ± 6.0 weeks met inclusion criteria. All had been conducted in China. HupA outperformed comparators on the following outcome measures: the Wechsler Memory Scale-Revised including memory quotient (weighted mean difference (WMD: 10.59; 95% confidence interval (CI): 5.65, 15.53; p < 0.0001); Wechsler Adult Intelligence Scale-Revised including verbal intelligence quotient (IQ), performance IQ, and full IQ (WMD: 3.97 to 5.66; 95%CI: 0.20, 8.58; p = 0.01 to 0.00001); Wisconsin Card Sorting Test including response administer and non-perseverative errors (WMD: -12.79 to -12.29; 95%CI: -23.70, -0.88; p = 0.03 to 0.003). In studies using the Positive and Negative Syndrome Scale (n = 7)/Brief Psychiatric Rating Scale (n = 1), the differences in total score were significant (standard mean difference: -0.77; 95%CI: -1.27, -0.27; p = 0.002). All-cause discontinuation (risk ratio: 0.67; 95%CI: 0.36, 1.24; p = 0.20) and adverse events were similar between groups. " It is possible that WMD (weighted mean difference) suggests 10.59, 3.97, IQ piint increase, with a 12.79 (WMD) reduction of errors. However I may be wildly misinterpreting the data. However I did read a different science paper reference (unfindable) that said it increased IQ from 104 to 114.

More RCTs are needed

Recent Cochrane reliable reviews have failed to show the effectiveness of huperzine A on vascular dementia and Alzheimer's disease (AD), however this seems to occur due to the lack of reliable contemporary RCTs (randomized controlled studies). To my mind, and after extensive research on the Pubmed studies, huperzine A seems promising on cognitive decline (especially on age - related), however more studies on humans are needed. The proper dose is also a question, as well as using on studies pharmaceutical forms with high bioavailability. Comparing to the rest AchE inhibotors, huperzine A seems more safer with less adverse effects. Moreover, further mechanisms, than inhibition of AchE, are implicated, such as antioxidant properties.688dim (talk) 20:05, 3 July 2013 (UTC)[reply]